Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Our site is under planned maintenance. At this time, you will not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Bioactive Lipids in Metabolic Syndrome

WEBINAR

Only

Bioactive Lipids in Metabolic Syndrome

Tuesday, June 8, 2021, 10:30 AM - 5:10 PM EDT

Presented By

Biochemical Pharmacology Discussion Group

The New York Academy of Sciences

 

Cardiometabolic disease refers to a cluster of related diseases of metabolism, which include cardiovascular disease, Type-2 diabetes, and nonalcoholic fatty liver disease (NAFLD/NASH).  The prevalence of these diseases is increasing and represents a critical threat to public health. In recent years, bioactive lipids have emerged as key mediators of cardiometabolic disease. Greater appreciation of the importance of bioactive lipids is due both to the development of “omics” technologies that have revealed new details of their functions, and to numerous genetic association studies that have linked lipid modifying enzymes to cardiovascular disease, Type-2 diabetes and NASH. As bioactive lipids are critical regulators of essential cellular processes, targeting them in disease contexts will require detailed knowledge of their behavior and regulatory mechanisms.

To address this challenge, this meeting will integrate recent data detailing the roles of bioactive lipids across multiple cardiometabolic diseases, with the aim of identifying key lipid species and pathways that might be viable therapeutic targets for multiple disease indications.

Call for Abstracts

You are invited to submit a poster abstract to be considered for a virtual poster session and short talks. For submission instructions, please visit our online portal here. The deadline for abstract submission is April 13, 2021.

Registration

Member
$30
Nonmember Academia, Faculty, etc.
$65
Nonmember Corporate, Other
$85
Nonmember Not for Profit
$65
Nonmember Student, Undergrad, Grad, Fellow
$45
Member Student, Post-Doc, Fellow
$15

Keynote Speaker

Edward Dennis, PhD

University of California, San Diego

Speakers

Barbara Kahn, MD

Harvard Medical School

Gerald Shulman, MD, PhD

Yale School of Medicine

Susan Smyth, MD, PhD

University of Kentucky

Scientific Organizing Committee

Edward Dennis, PhD

University of California, San Diego

Gregory Tesz, PhD

Pfizer

Michelle Clasquin, PhD

Pfizer

Min Wan, PhD

Pfizer

Sara Donnelly, PhD

The New York Academy of Sciences

Sonya Dougal, PhD

The New York Academy of Sciences